Saturday, March 30, 2019

Top 5 High Tech Stocks To Own Right Now

tags:WTI,AVK,HRTX,ISRG,ADAP,

Ice cream fans that are hoping to get their hands on a free Dairy Queen Blizzard are in luck.

Source: Shutterstock

A new offer from the restaurant chain will allow customers to pick up one free Dairy Queen Blizzard. However, there are a few things they need to know about the offer before running off to their local store.

The offer is only available for one free Dairy Queen Blizzard of the treat size. Also, customers can’t just walk in and expect a free DQ Blizzard. Instead, they will have to download the company’s mobile app and register for an account.

Top 5 High Tech Stocks To Own Right Now: W&T Offshore Inc.(WTI)

Advisors' Opinion:
  • [By Joseph Griffin]

    W&T Offshore, Inc. (NYSE:WTI) – Equities research analysts at Seaport Global Securities lifted their Q3 2018 EPS estimates for shares of W&T Offshore in a research report issued to clients and investors on Wednesday, September 26th. Seaport Global Securities analyst J. Aschenbeck now forecasts that the oil and gas company will post earnings per share of $0.16 for the quarter, up from their prior estimate of $0.14. Seaport Global Securities has a “Buy” rating on the stock. Seaport Global Securities also issued estimates for W&T Offshore’s Q1 2019 earnings at $0.21 EPS, Q2 2019 earnings at $0.18 EPS, Q3 2019 earnings at $0.18 EPS, Q4 2019 earnings at $0.19 EPS and FY2019 earnings at $0.76 EPS.

  • [By Dan Caplinger]

    The stock market had a mixed day on Wednesday, with gains for the Dow Jones Industrial Average coming largely at the expense of the tech-heavy Nasdaq Composite, as well as smaller-company stocks. Investors were encouraged by solid economic data showing strength in the housing market, and strength in the financial sector was especially helpful for the Dow. Nervousness about potential regulation of high-flying tech stocks dampened market sentiment to some extent, but a few individual stocks posted sizable gains. GW Pharmaceuticals (NASDAQ:GWPH), Baidu (NASDAQ:BIDU), and W&T Offshore (NYSE:WTI) were among the best performers on the day. Here's why they did so well.

  • [By Shane Hupp]

    Weatherly International plc (LON:WTI) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 0.09 ($0.00) and last traded at GBX 0.19 ($0.00), with a volume of 58655113 shares. The stock had previously closed at GBX 0.19 ($0.00).

Top 5 High Tech Stocks To Own Right Now: Advent Claymore Convertible Securities and Income Fund(AVK)

Advisors' Opinion:
  • [By Max Byerly]

    Saba Capital Management L.P. lessened its stake in Advent Claymore Convertible Sec & Inc Fd (NYSE:AVK) by 91.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,101 shares of the investment management company’s stock after selling 255,542 shares during the period. Saba Capital Management L.P. owned 0.11% of Advent Claymore Convertible Sec & Inc Fd worth $384,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

  • [By Ethan Ryder]

    Advent Claymore Convertible Sec & Inc Fd (NYSE:AVK) insider Tracy V. Maitland purchased 50,000 shares of Advent Claymore Convertible Sec & Inc Fd stock in a transaction dated Thursday, September 6th. The shares were acquired at an average cost of $15.68 per share, for a total transaction of $784,000.00. Following the completion of the transaction, the insider now owns 12,000 shares of the company’s stock, valued at approximately $188,160. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

  • [By Ethan Ryder]

    Advent Claymore Convertible Sec & Inc Fd (NYSE:AVK) VP Tony Huang bought 2,066 shares of the business’s stock in a transaction dated Wednesday, September 5th. The stock was acquired at an average cost of $15.66 per share, for a total transaction of $32,353.56. Following the completion of the acquisition, the vice president now directly owns 7,100 shares in the company, valued at $111,186. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Top 5 High Tech Stocks To Own Right Now: Heron Therapeutics, Inc. (HRTX)

Advisors' Opinion:
  • [By Max Byerly]

    Heron Therapeutics Inc (NASDAQ:HRTX) – Equities researchers at Cantor Fitzgerald issued their FY2019 earnings per share (EPS) estimates for shares of Heron Therapeutics in a report issued on Thursday, July 19th. Cantor Fitzgerald analyst L. Chen anticipates that the biotechnology company will post earnings of ($0.23) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $50.00 price objective on the stock.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Dan Caplinger]

    Thursday was a poor day on Wall Street, with major benchmarks giving up about 0.5%-1% across the board. Trade concerns remain the focal point for market participants, with the latest controversy over U.S. immigration policy posing a potential threat to relations with traditional American allies abroad as well. Even with worries on a big-picture level, some individual companies had good news that sent their shares higher. Stitch Fix (NASDAQ:SFIX), Barnes & Noble Education (NYSE:BNED), and Heron Therapeutics (NASDAQ:HRTX) were among the best performers on the day. Here's why they did so well.

  • [By George Budwell]

    Shares of the commercial-stage biotech Heron Therapeutics (NASDAQ:HRTX) gained as much as 36.3% today on abnormally high volume. What triggered this massive surge higher? 

  • [By George Budwell]

    As things stand now, Cara's immediate future hinges directly on the strength of Korsuva's late-stage results in both postoperative pain and CKD-associated pruritus. Having said that, I think investors should largely consider the drug's postoperative pain indication as icing on the cake at this point. Heron Therapeutics' (NASDAQ:HRTX)experimental pain medicine HTX-011, after all, appears to have a sizable advantage in terms of efficacy over Korsuva based on the trial data so far. And Heron is almost certainly going to beat Cara to market by several years as well, giving it a formidable first-mover advantage. 

Top 5 High Tech Stocks To Own Right Now: Intuitive Surgical Inc.(ISRG)

Advisors' Opinion:
  • [By Brian Feroldi]

    TransEnterix (NYSEMKT:TRXC) recently surprised investors on the upside when it reported its first-quarter results. The company's Senhance surgical system is off to a fast start right out of the gate, and it has attracted a lot of positive attention from the medical community. This just goes to show how much demand is out there for an alternative to Intuitive Surgical's (NASDAQ: ISRG) dominant da Vinci platform. 

  • [By Anders Bylund]

    Shares of Intuitive Surgical (NASDAQ:ISRG) rose 10.2% in August 2018, according to data from S&P Global Market Intelligence. The maker of the da Vinci robotic surgery platform and its associated tools didn't need any actual news to keep its impressive market momentum going.

  • [By Motley Fool Staff]

    In this segment from MarketFoolery, host Chris Hill and Motley Fool Asset Management's Bill Barker consider the case for healthcare innovator Intuitive Surgical (NASDAQ:ISRG), which has been on a tear for the past few years. Its pricey robots are growing ever more common and popular with hospitals and doctors, and based on the reaction of the market, investors must expect its current sales growth pace to continue.

  • [By Daniel Sparks]

    As earnings season begins to kick into gear, next week features stocks of all shapes and sizes. But two stocks I'll be watching are growth stocks Netflix (NASDAQ:NFLX) and Intuitive Surgical (NASDAQ:ISRG). Both companies are benefiting from double-digit growth in revenue and earnings per share. When these companies report their second-quarter results next week, investors will be watching to see if they can keep executing well on the growth opportunities before them.

Top 5 High Tech Stocks To Own Right Now: Adaptimmune Therapeutics plc(ADAP)

Advisors' Opinion:
  • [By ]

    Adaptimmune Therapeutics (ADAP) : "If you've speculated on this one, you've won. Let's move on."

    Icahn Enterprises (IEP) : "I don't really know what they own so I can't recommend it."

  • [By Ethan Ryder]

    Adaptimmune Therapeutics (NASDAQ:ADAP) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.20, Bloomberg Earnings reports. Adaptimmune Therapeutics had a negative return on equity of 32.26% and a negative net margin of 185.39%. During the same quarter in the prior year, the business earned ($3.00) EPS.

  • [By Logan Wallace]

    Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

Friday, March 29, 2019

The new face of Papa John's Pizza: Shaq

Shaquille O'Neal is joining the Papa John's board of directors and has inked a deal to be the company's brand ambassador.

"In addition to his business acumen, Shaquille understands how to build lasting connections with consumers and energize employees," said Papa John's president and CEO Steve Ritchie. 

Friday's news is the latest in a string of changes for the world's third-largest pizza chain, which is still working to remake its image in the wake of scandal.

The company was rocked in July 2018 after news reports surfaced that founder and chairman John Schnatter used a racial slur during a media training session. 

.oembed-frame { width: 100%; height: 100%; margin: 0; border: 0; }

Tysons chicken recall: More than 69,000 pounds of chicken strips recalled because they may contain metal

Going into space: Toyota plans to develop a 6-wheeled moon rover

The news came about eight months after Schnatter's remarks blaming poor sales on the NFL's handling of protests during the national anthem.

Stocks plummeted and Schnatter soon disappeared from television and promotional materials, as the company attempted to distance itself from its chief pitchman.

Now, O'Neal has signed a marketing agreement with the company, which has more than 5,000 stores and 1,200 employees.

Retired Hall of Fame basketball player Shaquille O'Neal smiles as he talks to reporters during an NBA basketball news conference in Miami on Dec. 22, 2016. (Photo: Alan Diaz, AP)

"I have truly enjoyed the high-quality Papa John's product for years and am excited to be able to help Papa John's raise their game to new heights," O'Neal said in a statement. "Papa John's is building a better culture, and I want to be a part of improving the Company from the inside out."

It's unclear what form that marketing agreement will take, though Shaq has long been the public face of many companies. 

In addition to his lengthy NBA career spanning from 1992 until 2011, he's taken his large personality off the court with ventures in music, film and television. 

The NBA Hall of Famer can already be seen on television as an analyst on Inside The NBA and as a spokesperson for a variety of products, including IcyHot, Carnival cruises and The General insurance.

No stranger to the restaurant industry, O'Neal is the founder and owner of Big Chicken, a fried chicken restaurant in Las Vegas, and Shaquille's, a restaurant in Los Angeles. 

He's also the owner of a Krispy Kreme Doughnuts franchise in Atlanta, and as part of his pizza partnership he'll become an investor in nine Papa John's restaurants in the Atlanta area.

"We are thrilled to partner with Shaquille and welcome him to the Papa John's Board," said Jeff Smith, chairman of the Papa John's board. "Shaquille has an excellent entrepreneurial background, including as a restaurant franchise owner, and is a natural creative marketer."

NEWSLETTERSGet the Managing Your Money newsletter delivered to your inboxWe're sorry, but something went wrongA collection of articles to help you manage your finances like a pro.Please try again soon, or contact Customer Service at 1-800-872-0001.Delivery: FriInvalid email addressThank you! You're almost signed up for Managing Your MoneyKeep an eye out for an email to confirm your newsletter registration.More newsletters

Smith was named chairman of the board of directors last month after company executives agreed to sell a $200 million stake to Starboard Value, a New York-based investment fund that Smith leads. 

O'Neal's entry comes on the heels of a deal struck with Schnatter earlier this month that avoided an all-out public battle over his membership on the board. 

John Schnatter, founder of Papa John's Pizza. - Oct. 2, 2017 (Photo: Sam Upshaw Jr./The Courier Journal )

While a special committee of the company's directors eventually forced Schnatter out as chairman, he remained on the board. He still owns 9.9 million shares, a 26 percent stake in the company. 

Per the agreement, Schnatter agreed to resign from the board of directors while retaining a say in picking his successor. 

He also agreed to drop a lawsuit pending in Delaware that challenged a provision that prevented him from "acting in concert" with other shareholders.

While company leadership has made a number of changes, including a new customer loyalty program and revised menu items, Papa John's continues to struggle to emerge from the scandal.

Last month, the company reported a drop in North American sales of 7.3 percent for the year and 8.1 percent for the fourth quarter of 2018.

Full year net income declined from $94.7 million in 2017 to $22.8 million last year.

"This will take time," Ritchie, the company's CEO, told analysts last month.

The Courier Journal previously reported that re-branding and reinvention cost the company more than $51 million in special charges last year, including $15.4 million going to help ailing franchisees. 

Papa John's predicted last month it would spend an additional $30 million to $50 million in the first half of this year.

Ritchie has said he's confident the strategy will work in the long run, despite the short-term pain.

Reporter Grace Schneider contributed to this story. Reporter Matthew Glowicki can be reached at 502-582-4989 or mglowicki@courier-journal.com.

Monday, March 25, 2019

Top 10 Clean Energy Stocks To Invest In Right Now

tags:CYOU,ARRS,DEPO,ABBV,MARK,AKR,ORAN,DBL,CVV,UFCS, &l;p&g;&l;img class=&q;dam-image getty size-large wp-image-1024561716&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1024561716/960x0.jpg?fit=scale&q; data-height=&q;540&q; data-width=&q;960&q;&g; (Photo by Hu Weiguo/VCG via Getty Images)

&l;span&g;For over two thousands years, scientists have experimented with ways to capture the energy of the sun. Archimedes in 212 BC, for instance, famously rigged a system of mirrors that was used to spark fires aboard enemy ships&a;mdash;sort of like an ancient heat ray. &l;/span&g;

&l;span&g;Over time, the methods of capturing solar energy have obviously evolved (and perhaps become a bit less dramatic) but there are persisting questions for scientists: How do you best store the energy from the sun, and how do you distribute it cheaply and efficiently at scale?&l;/span&g;

&l;span&g;From my perspective, as a person who cares deeply about the environment and the future of our planet, those questions are among society&a;rsquo;s most pressing concerns. Global warming is an existential threat to humanity, and we must reduce our dependence on fossil fuels. But I&a;rsquo;m also an investor who embraces the belief that fossil fuels and carbon emissions will eventually be phased out entirely. I&a;rsquo;ve been&a;nbsp;&l;a href=&q;https://www.wormcapital.com/insights/clean-energy-revolution-worm-capital&q; target=&q;_blank&q;&g;calling it&l;/a&g; the &a;ldquo;clean energy revolution,&a;rdquo; and to get there, we must cultivate new ideas, start anew, and listen to the boldest visionaries who are addressing these problems at a global scale. &l;/span&g;

Top 10 Clean Energy Stocks To Invest In Right Now: Changyou.com Limited(CYOU)

Advisors' Opinion:
  • [By Rick Munarriz]

    Continuing its turnaround may seem to be an applause-worthy event. This is the third quarter in a row that year-over-year revenue growth tops 20%. However, weak guidance and continuing softness in its flagship display advertising business are sending the stock that was hitting two-year highs just six months ago to fresh 10-year lows. Spun-off subsidiaries Sogou (NYSE:SOGO) and Changyou.com (NASDAQ:CYOU) are also moving lower on Wednesday. 

  • [By Motley Fool Transcribers]

    ChangYou.com  (NASDAQ:CYOU)Q4 2018 Earnings Conference CallFeb. 01, 2019, 12:30 p.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator

  • [By Ethan Ryder]

    Shenzhen Xunlei Networking Technologies (NASDAQ: XNET) and Changyou (NASDAQ:CYOU) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

  • [By Ethan Ryder]

    Changyou.Com Ltd (NASDAQ:CYOU)’s share price reached a new 52-week low during trading on Thursday . The stock traded as low as $15.57 and last traded at $15.67, with a volume of 2540 shares changing hands. The stock had previously closed at $15.83.

  • [By Logan Wallace]

    SAP (NYSE:SAP) and Changyou.Com (NASDAQ:CYOU) are both computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk and dividends.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers Changyou.com Limited (NASDAQ: CYOU) fell 27.5 percent to $21.35 in pre-market trading. Flex Ltd. (NASDAQ: FLEX) fell 19.7 percent to $13.36 in pre-market trading after a mixed fourth quarter report. Tandem Diabetes Care, Inc. (NASDAQ: TNDM) shares fell 10.5 percent to $7.15 in pre-market trading following mixed Q1 results. Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) fell 8.1 percent to $2.16 in pre-market trading. LogMeIn Inc (NASDAQ: LOGM) fell 8 percent to $110.05 in pre-market trading. LogMeIn reported upbeat earnings for its first quarter, but issued weak second quarter and FY18 earning guidance. United States Steel Corporation (NYSE: X) fell 6.2 percent to $35.36 in pre-market trading following Q1 results. Deutsche Bank Aktiengesellschaft (NYSE: DB) fell 5 percent to $13.63 in pre-market trading. Sony Corporation (NYSE: SNE) shares fell 4.3 percent to $48.00 in pre-market trading after reporting Q4 results. Colgate-Palmolive Company (NYSE: CL) shares fell 4 percent to $64.00 in pre-market trading. Colgate-Palmolive posted upbeat Q1 earnings, while sales missed estimates

Top 10 Clean Energy Stocks To Invest In Right Now: Arris Group Inc(ARRS)

Advisors' Opinion:
  • [By Shane Hupp]

    A number of hedge funds and other institutional investors have recently bought and sold shares of the business. grace capital grew its position in ARRIS International by 37.5% in the 4th quarter. grace capital now owns 5,500 shares of the communications equipment provider’s stock worth $168,000 after purchasing an additional 1,500 shares during the last quarter. US Bancorp DE grew its position in ARRIS International by 8.3% in the 3rd quarter. US Bancorp DE now owns 37,066 shares of the communications equipment provider’s stock worth $965,000 after purchasing an additional 2,849 shares during the last quarter. Tocqueville Asset Management L.P. grew its position in ARRIS International by 1.8% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 270,223 shares of the communications equipment provider’s stock worth $7,023,000 after purchasing an additional 4,888 shares during the last quarter. Delta Capital Management LLC acquired a new stake in ARRIS International in the 4th quarter worth $227,000. Finally, Cerebellum GP LLC acquired a new stake in ARRIS International in the 4th quarter worth $254,000. Institutional investors own 82.25% of the company’s stock.

    ILLEGAL ACTIVITY WARNING: “ARRIS International plc (ARRS) SVP Sells $201,041.00 in Stock” was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/4216566/arris-international-plc-arrs-svp-sells-201041-00-in-stock.html.

    ARRIS International Company Profile

  • [By Max Byerly]

    Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) and ARRIS International (NASDAQ:ARRS) are both computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

  • [By Max Byerly]

    Strs Ohio increased its stake in shares of ARRIS International plc (NASDAQ:ARRS) by 6.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,728,995 shares of the communications equipment provider’s stock after buying an additional 273,995 shares during the quarter. Strs Ohio owned about 2.54% of ARRIS International worth $115,600,000 at the end of the most recent quarter.

  • [By Max Byerly]

    Earnest Partners LLC increased its position in shares of ARRIS International plc (NASDAQ:ARRS) by 0.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 591,282 shares of the communications equipment provider’s stock after buying an additional 2,531 shares during the period. Earnest Partners LLC owned 0.32% of ARRIS International worth $15,710,000 as of its most recent filing with the SEC.

  • [By Lee Jackson]

    Jefferies sees this stock as another top value play in 2018. It has been a favorite at the firm for some time and remains a top small-cap pick. Arris International PLC (NASDAQ: ARRS) provides media entertainment and data communications solutions in the United States and internationally. It operates through two segments.

  • [By Joseph Griffin]

    Signition LP reduced its position in ARRIS International plc (NASDAQ:ARRS) by 11.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 30,577 shares of the communications equipment provider’s stock after selling 3,836 shares during the quarter. ARRIS International makes up about 1.0% of Signition LP’s investment portfolio, making the stock its 22nd biggest holding. Signition LP’s holdings in ARRIS International were worth $812,000 at the end of the most recent reporting period.

Top 10 Clean Energy Stocks To Invest In Right Now: DepoMed Inc.(DEPO)

Advisors' Opinion:
  • [By Shane Hupp]

    Depomed (NASDAQ:DEPO) was upgraded by Janney Montgomery Scott from a “neutral” rating to a “buy” rating in a report released on Monday.

  • [By Shane Hupp]

    Depomed Inc (NASDAQ:DEPO) has received an average rating of “Hold” from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $8.67.

  • [By Todd Campbell]

    After updating investors on its restructuring and boosting its full-year guidance, shares of Depomed Inc. (NASDAQ:DEPO) were up 23.2% on Thursday.

  • [By Logan Wallace]

    SG Americas Securities LLC bought a new stake in Depomed Inc (NASDAQ:DEPO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 80,583 shares of the specialty pharmaceutical company’s stock, valued at approximately $537,000. SG Americas Securities LLC owned about 0.13% of Depomed as of its most recent filing with the Securities & Exchange Commission.

  • [By Stephan Byrd]

    Depomed (NASDAQ:DEPO) released its earnings results on Thursday. The specialty pharmaceutical company reported $0.28 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.16, Bloomberg Earnings reports. The firm had revenue of $128.40 million during the quarter, compared to analyst estimates of $65.77 million. Depomed had a negative return on equity of 45.19% and a negative net margin of 26.92%. The business’s quarterly revenue was up 41.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.07 earnings per share.

  • [By Joseph Griffin]

    Depomed (NASDAQ:DEPO) dropped 0% during mid-day trading on Tuesday . The stock traded as low as $6.58 and last traded at $6.69. Approximately 3,739,419 shares traded hands during mid-day trading, an increase of 190% from the average daily volume of 1,287,687 shares. The stock had previously closed at $6.69.

Top 10 Clean Energy Stocks To Invest In Right Now: AbbVie Inc.(ABBV)

Advisors' Opinion:
  • [By Chris Lange]

    The number of shares short in AbbVie Inc. (NYSE: ABBV) increased to 15.66 million, compared to the previous 15.25 million. The stock was trading at $91.36, in a 52-week range of $64.61 to $125.86.

  • [By Michael A. Robinson]

    To hear Wall Street tell it, AbbVie Inc. (NYSE: ABBV) drove right into a ditch last month.

    Here's the thing. The company announced results of a Phase 2 trial on March 22 that were disappointing but hardly fatal. The results mean AbbVie won't seek fast-track approval for its promising antibody-drug conjugate, Rova-T, but it still expects to be able to take it to market in the near future.

  • [By Chris Neiger, Anders Bylund, and Todd Campbell]

    To help you track down a few of these companies for your portfolio, we reached out to some Motley Fool contributors for dividend stock ideas. They came back with Uniti Group (NASDAQ:UNIT), AbbVie (NYSE:ABBV), and American Tower (NYSE:AMT). Here's why.

  • [By Keith Speights]

    Which drugs rank at the top of EvaluatePharma's list? Here are the five biggest blockbusters of the future -- and the five companies that are poised to profit from these drugs: AbbVie (NYSE:ABBV), Merck (NYSE:MRK), Celgene (NASDAQ:CELG), Bristol-Myers Squibb (NYSE:BMY), and Pfizer (NYSE:PFE). 

Top 10 Clean Energy Stocks To Invest In Right Now: Remark Media, Inc.(MARK)

Advisors' Opinion:
  • [By Joseph Griffin]

    Remark (NASDAQ: MARK) and Global Eagle Entertainment (NASDAQ:ENT) are both small-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

  • [By Max Byerly]

    News headlines about Remark (NASDAQ:MARK) have trended positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Remark earned a news impact score of 0.28 on Accern’s scale. Accern also gave news articles about the information services provider an impact score of 45.6127908528614 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

  • [By Lisa Levin]

    Shares of Remark Holdings, Inc. (NASDAQ: MARK) were down 16 percent to $5.20. Remark Holdings posted Q1 GAAP loss of $0.43 per share on sales of $16.724 million.

  • [By Stephan Byrd]

    News stories about Remark (NASDAQ:MARK) have trended positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Remark earned a media sentiment score of 0.30 on Accern’s scale. Accern also assigned media coverage about the information services provider an impact score of 46.6326043635021 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

  • [By Lisa Levin] Companies Reporting Before The Bell Hanwha Q CELLS Co., Ltd. (NASDAQ: HQCL) is estimated to report quarterly earnings at $0.14 per share on revenue of $438.40 million. Remark Holdings, Inc. (NASDAQ: MARK) is projected to report quarterly loss at $0.35 per share on revenue of $19.45 million. Athenex, Inc. (NYSE: ATNX) is expected to report quarterly loss at $0.07 per share on revenue of $35.14 million. Mazor Robotics Ltd. (NASDAQ: MZOR) is estimated to report quarterly loss at $0.08 per share on revenue of $15.14 million. Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) is projected to report a quarterly loss at $0.14 per share. SuperCom Ltd. (NASDAQ: SPCB) is expected to report quarterly earnings at $0.08 per share on revenue of $9.50 million. Lonestar Resources US Inc. (NASDAQ: LONE) is projected to report quarterly loss at $0.04 per share on revenue of $30.68 million. Nine Energy Service, Inc. (NASDAQ: NINE) is estimated to report quarterly earnings at $0.1 per share on revenue of $165.76 million. VEON Ltd. (NASDAQ: VEON) is projected to report quarterly earnings at $0.05 per share on revenue of $212.00 million.

     

Top 10 Clean Energy Stocks To Invest In Right Now: Acadia Realty Trust(AKR)

Advisors' Opinion:
  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Acadia Realty Trust (AKR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Motley Fool Transcribing]

    Acadia Realty Trust (NYSE:AKR) Q4 2018 Earnings Conference CallFeb. 14, 2019 12:00 p.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator

  • [By Shane Hupp]

    Corecivic (NYSE:CXW) and Acadia Realty Trust (NYSE:AKR) are both mid-cap finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Top 10 Clean Energy Stocks To Invest In Right Now: Orange(ORAN)

Advisors' Opinion:
  • [By Shane Hupp]

    Bank of America Corp DE boosted its holdings in Orange SA (NYSE:ORAN) by 5.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,916,094 shares of the technology company’s stock after purchasing an additional 330,125 shares during the quarter. Bank of America Corp DE owned approximately 0.22% of Orange worth $98,621,000 at the end of the most recent quarter.

  • [By Anders Bylund, Timothy Green, and Dan Caplinger]

    The trick is to separate high-quality income generators from their lower-quality peers. So we asked a few of your fellow investors here at The Motley Fool to share their best dividend ideas with yields of 4% or more. Read on to see why they recommend tech titan International Business Machines (NYSE:IBM), international telecom Orange (NYSE:ORAN), and energy giant ExxonMobil (NYSE:XOM).

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Orange (ORAN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Orange (ORAN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    ValuEngine downgraded shares of Orange (NYSE:ORAN) from a buy rating to a hold rating in a research report released on Monday morning.

    ORAN has been the topic of several other reports. Zacks Investment Research cut Orange from a hold rating to a sell rating in a research report on Wednesday, April 25th. BNP Paribas raised Orange from an underperform rating to a neutral rating in a research report on Tuesday, January 23rd. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Orange has a consensus rating of Hold and an average price target of $19.00.

Top 10 Clean Energy Stocks To Invest In Right Now: DoubleLine Opportunistic Credit Fund(DBL)

Advisors' Opinion:
  • [By Joseph Griffin]

    Doubleline Opportunistic Credit Fund (NYSE:DBL) declared a monthly dividend on Monday, October 1st, NASDAQ reports. Stockholders of record on Thursday, October 11th will be paid a dividend of 0.167 per share by the investment management company on Wednesday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 9.98%. The ex-dividend date of this dividend is Wednesday, October 10th.

  • [By Max Byerly]

    News headlines about Doubleline Opportunistic Credit Fund common stock (NYSE:DBL) have been trending somewhat positive on Monday, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Doubleline Opportunistic Credit Fund common stock earned a news impact score of 0.04 on Accern’s scale. Accern also gave media stories about the investment management company an impact score of 47.2090833571026 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

  • [By Logan Wallace]

    Doubleline Opportunistic Credit Fund common stock (NYSE:DBL) announced a monthly dividend on Friday, June 1st, Zacks reports. Investors of record on Thursday, June 14th will be paid a dividend of 0.167 per share by the investment management company on Friday, June 29th. This represents a $2.00 dividend on an annualized basis and a yield of 9.41%. The ex-dividend date is Wednesday, June 13th.

Top 10 Clean Energy Stocks To Invest In Right Now: CVD Equipment Corporation(CVV)

Advisors' Opinion:
  • [By Ethan Ryder]

    News headlines about CVD Equipment (NASDAQ:CVV) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CVD Equipment earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news stories about the industrial products company an impact score of 46.7103888113407 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

  • [By Shane Hupp]

    News coverage about CVD Equipment (NASDAQ:CVV) has been trending somewhat positive this week, according to Accern. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CVD Equipment earned a news impact score of 0.07 on Accern’s scale. Accern also assigned news headlines about the industrial products company an impact score of 47.2607770405573 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Top 10 Clean Energy Stocks To Invest In Right Now: United Fire Group, Inc(UFCS)

Advisors' Opinion:
  • [By Lee Jackson]

    United Fire Group Inc. (NASDAQ: UFCS) was downgraded to hold from buy at Sandler O'Neill. The 52-week trading range for the shares has been $38.95 to $58.46. The stock closed Monday at $56, so this could be another valuation call.

  • [By Ethan Ryder]

    News stories about United Fire Group (NASDAQ:UFCS) have been trending somewhat positive on Wednesday, Accern reports. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. United Fire Group earned a coverage optimism score of 0.01 on Accern’s scale. Accern also gave news articles about the insurance provider an impact score of 48.2793119465098 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

  • [By Motley Fool Transcribers]

    United Fire Group Inc  (NASDAQ:UFCS)Q4 2018 Earnings Conference CallFeb. 20, 2019, 10:00 a.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator

  • [By Stephan Byrd]

    United Fire Group (NASDAQ:UFCS) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on United Fire Group (UFCS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    United Fire Group (NASDAQ:UFCS) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday.

Thursday, March 21, 2019

D-Street Buzz: Auto stocks slip further led by Hero Moto, Bharti Airtel sheds 2%; Bajaj Finance gain

The Indian stock market has turned negative in the afternoon trade with Nifty50 down 3 points, trading at 11,439 while the Sensex has added 11 points and is trading at 38,036.

At 1455 hours, Nifty IT along with Nifty Auto shed over a percent dragged by Wipro, Infosys, Tata Consultancy Services, Tech Mahindra, HCL Tech and Infibeam Avenue.

From the auto space, the top losers are Maruti Suzuki followed by Hero MotoCorp, Motherson Sumi, Eicher Motors, Bharat Forge, Bajaj Auto and Ashok Leyland.

Selective PSU banks continue to trade in the red led by State Bank of India, Punjab National Bank and Central Bank of India.

related news Prabhat Dairy locked in upper circuit for 2nd day in a row Hindustan Aeronautics gains 6% as company announces hefty dividend Ratnamani Metals gains 2% on order win worth Rs 298 crore

From the midcap space, the top losers are 3M India, CG Consumer, GE T&D, GRUH Finance, Reliance Communications, Shriram Transport and Tata Global Beverage among others.

From the small-cap space, the top losers are Action Construction, Adan Offshore, Adani Transmission, Aksh Optifibre, Allcargo Logistics, Amtek Auto, Apar Industries, Arcotech, Arihant Superstructures, RPP Infra, Indocount Industries, Gayatri Projects and TTK Prestige among others.

The top Nifty gainers included Indian Oil Corporation, BPCL, HPCL, JSW Steel and Bajaj Finance while the top losers included Maruti, Wipro, Hero Moto, Bharti Airtel and HCL Tech.

The most active stocks were Maruti Suzuki, ICICI Bank, Just Dial, Reliance Industries and HDFC Bank.

HDFC Bank, ICICI Bank, Axis Bank, Karnataka Bank, UPL, SRF, Jubilant Life Sciences, IDFC First Bank, PVR and Alok Industries have hit 52-week high on NSE.

The breadth of the market favoured the declines with 711 stocks advancing and 1,023 declining while 368 remained unchanged. On the BSE, 1,061 stocks advanced, 1,582 declined and 172 remained unchanged.

Disclosure: Reliance Industries Ltd. is the sole beneficiary of Independent Media Trust which controls Network18 Media & Investments Ltd. First Published on Mar 18, 2019 03:26 pm

Sunday, March 17, 2019

The Numbers Say Eli Lilly Stock Has Still More Upside For Investors

Shares of global pharma giant Eli Lilly (NYSE:LLY) have performed incredibly well over the past decade, rising more than 350% as the market gained 300%. But, the LLY stock rally has kicked into overdrive during the past year. Shares are up more than 60% while the Dow Jones Industrial Average is pretty much flat over that same stretch.

This big rally against the backdrop of a flat market has some investors concerned. Are these gains sustainable? Or is LLY stock out over its skis here?

As we head into the close of the first quarter, the numbers support the bull thesis. Eli Lilly stock is a powered by healthy tailwinds from pharma product portfolio expansion and increased global healthcare spend. Rounding out this story are steady positive revenue growth, margin expansion and healthy profit growth. Assuming this persists — and it should — LLY stock has upside to prices above $135 in 2019.

Eli Lilly stock currently trades around $125, so the shares should reasonably head 8% higher into the end of the year. Coupled with a 2%+ yield, LLY stock should produce about 10% return from here over the next 12 months. That is fairly good return from of a low-risk, stable-growth company like Lilly. As such, the bull thesis here looks pretty good.

Stable Growth Story

In the big picture, Eli Lilly has a large and growing portfolio of drugs and treatments that span a wide range of illnesses and conditions. It has broad exposure to the global healthcare market. That market is largely characterized by competitive stability, enduring demand, and mild growth.

Zooming in, Eli Lilly has a heavy focus on the oncology and diabetes markets, including a distinguished leadership in the diabetes market with a robust pipeline of insulin-related products. These sub-sectors of the global healthcare are likewise characterized by competitive stability, enduring demand, and mild growth.

As such, so long as Eli Lilly management continues to execute on its product road-map and maintain the company’s competitive positioning in the global healthcare market, this company will benefit from stable and steady revenue and profit growth.


Compare Brokers

This should happen. Management has successfully navigated the healthcare market over the past decade. During that time, they’ve not just maintained Eli Lilly’s competitive positioning. They’ve actually improved it. There’s no reason to believe that this won’t continue. Also, the company has a promising pipeline of forthcoming products. Gross margins are guided to head higher, while opex rates have room to fall.

Overall, the growth story underlying Eli Lilly stock is stable and solid. That stable and solid narrative should be enough to keep the shares on a winning track.

Numbers Confirm Further Upside Potential

Given reasonable long-term growth assumptions, it is reasonable to conclude that LLY stock is slightly undervalued at the current moment.

The math here is very simple: U.S. healthcare spend is expected to rise by 5.5% per year over the next several years, and global healthcare spend will likely rise at a similar, if not higher, rate. Allowing for competitive slippage but also accounting for management’s strong track record and the healthy product pipeline, that should flow into roughly 5% revenue growth per year for Eli Lilly. Meanwhile, margins should track higher as the company leverages acquisitions and the current pipeline — not internal R&D — to grow. Long term, operating margins have the potential to stabilize in the mid-30’s range.

Given those assumptions, I think Eli Lilly can do about $10 in EPS by 2025. Based on a historically average 20x forward multiple, that equates to a fiscal 2024 price target of $200. Discounted back by 8% per year (two points below my normal 10% discount rate to account for the yield), that results in a fiscal 2019 price target of over $135.

Bottom Line on LLY Stock

It increasingly appears that Eli Lilly is on a long term winning trajectory defined by stable mid-single-digit revenue growth and steady margin expansion. If so, LLY stock has the potential to hit $200 in the long run, implying healthy multi-year upside from current levels.

As of this writing, Luke Lango did not hold a position in any of the aforementioned

Friday, March 15, 2019

NEWTEK Business Services Corp (NEWT) Expected to Announce Earnings of $0.38 Per Share

Equities analysts forecast that NEWTEK Business Services Corp (NASDAQ:NEWT) will announce earnings per share of $0.38 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for NEWTEK Business Services’ earnings. The highest EPS estimate is $0.41 and the lowest is $0.35. NEWTEK Business Services posted earnings per share of $0.44 in the same quarter last year, which suggests a negative year-over-year growth rate of 13.6%. The company is expected to announce its next earnings results on Wednesday, May 1st.

On average, analysts expect that NEWTEK Business Services will report full-year earnings of $2.05 per share for the current financial year, with EPS estimates ranging from $2.03 to $2.07. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for NEWTEK Business Services.

Get NEWTEK Business Services alerts:

NEWTEK Business Services (NASDAQ:NEWT) last announced its quarterly earnings data on Wednesday, March 6th. The business services provider reported $0.57 EPS for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.04. The firm had revenue of $14.66 million during the quarter, compared to the consensus estimate of $12.85 million. NEWTEK Business Services had a net margin of 102.01% and a return on equity of 8.51%.

A number of research firms have recently issued reports on NEWT. TheStreet downgraded shares of NEWTEK Business Services from a “b” rating to a “c+” rating in a research report on Monday. Compass Point began coverage on shares of NEWTEK Business Services in a research report on Friday, March 8th. They set a “neutral” rating and a $19.00 price target for the company. BidaskClub upgraded shares of NEWTEK Business Services from a “sell” rating to a “hold” rating in a research report on Monday, February 25th. Zacks Investment Research upgraded shares of NEWTEK Business Services from a “sell” rating to a “hold” rating in a research report on Wednesday, January 16th. Finally, LADENBURG THALM/SH SH upgraded shares of NEWTEK Business Services from a “neutral” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Friday, December 28th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. NEWTEK Business Services has a consensus rating of “Hold” and an average price target of $18.67.

In related news, CEO Barry Sloane purchased 3,000 shares of NEWTEK Business Services stock in a transaction dated Thursday, December 20th. The stock was bought at an average cost of $16.46 per share, for a total transaction of $49,380.00. Following the transaction, the chief executive officer now owns 1,012,911 shares in the company, valued at $16,672,515.06. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders have bought 4,812 shares of company stock valued at $79,679. Insiders own 6.30% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Capital Financial Planning LLC purchased a new position in shares of NEWTEK Business Services during the 4th quarter worth approximately $42,000. Advisory Services Network LLC increased its stake in shares of NEWTEK Business Services by 250.3% during the 4th quarter. Advisory Services Network LLC now owns 10,530 shares of the business services provider’s stock worth $184,000 after purchasing an additional 7,524 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in shares of NEWTEK Business Services by 8.0% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 10,712 shares of the business services provider’s stock worth $187,000 after purchasing an additional 797 shares in the last quarter. Fusion Family Wealth LLC increased its stake in shares of NEWTEK Business Services by 11.9% during the 4th quarter. Fusion Family Wealth LLC now owns 10,841 shares of the business services provider’s stock worth $189,000 after purchasing an additional 1,150 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of NEWTEK Business Services by 197.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,503 shares of the business services provider’s stock worth $241,000 after purchasing an additional 7,638 shares in the last quarter. 21.59% of the stock is owned by institutional investors and hedge funds.

NEWT stock opened at $20.47 on Monday. NEWTEK Business Services has a 12-month low of $15.59 and a 12-month high of $24.24. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.38 and a quick ratio of 0.38. The company has a market cap of $382.56 million, a PE ratio of 15.57, a P/E/G ratio of 3.32 and a beta of 1.39.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 15th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 7.82%.

About NEWTEK Business Services

Newtek Business Services Corp. is a business development company specializing in providing financial and business services to the small-and medium-sized business market in the United States. The firm also seeks to invest in early stage businesses. The firm seeks to makes both debt and equity investments.

Featured Story: Investing in Dividend Stocks

Get a free copy of the Zacks research report on NEWTEK Business Services (NEWT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Thursday, March 14, 2019

Hot Low Price Stocks To Invest In 2019

tags:BIDU,NHTC,COL,ZROZ,IOSP,

Retail giant Walmart (NYSE:WMT) isn’t too happy about the Trump administration enacting tariffs on Chinese imports and potential buyers of Walmart stock wonder how bad things could get.

Walmart recently wrote a letter to U.S. Trade Representative Robert Lighthizer, in which the company detailed how expanded tariffs on Chinese imports would adversely impact the retailer, its customers, and the U.S. economy. The short of it: tariffs will force Walmart to raise prices, which could have a negative affect on consumers, consumer spending, and U.S. economic activity.

If tariffs seem like a negative for Walmart stock, it’s because they are. Tariffs mean either Walmart has to absorb higher costs and operate at lower margins, or they have to raise prices. Walmart has made it clear that they will raise prices. Walmart, whose biggest value props are all-in-one convenience and “Everyday Low Prices,”stands to lose a sizable amount of traffic if prices go up.

Hot Low Price Stocks To Invest In 2019: Baidu Inc.(BIDU)

Advisors' Opinion:
  • [By Brian Stoffel]

    Chinese search giant Baidu (NASDAQ:BIDU) went public in 2005. After stumbling out of the IPO gate, it experienced the type of run-up that can create dynastic wealth for patient investors. Between early 2006 and mid-2011, shares of the company advanced 3,000%. In other words, in just five years, you could have turned a $10,000 investment into $300,000!

  • [By Chris Hill]

    Hill: We'll stick with video for a minute or two longer. Now that iQiyi is public -- you've talked about this before, is this of interest to you? Is this a stock you've already bought, or it's on the watch list? And for those who don't know, iQiyi was essentially spun out of Baidu (NASDAQ:BIDU). So, the Google of China spins out the Netflix of China. And as you said before, it seems like, if nothing else, it's a win for Baidu shareholders, because Baidu still has the ownership stake.

  • [By Leo Sun]

    Tencent's ecosystem covers lots of markets. WeChat, the most popular messaging app in China, grew its monthly active users (MAUs) 11% annually to 989 million last quarter. The expansion of WeChat -- which offers ride hailing, delivery services, e-commerce features, games, payments, and other services -- widens Tencent's moat against search giant Baidu (NASDAQ:BIDU) and e-commerce heavyweight Alibaba (NYSE:BABA).

  • [By Lisa Levin] Gainers Genprex, Inc. (NASDAQ: GNPX) jumped 46.7 percent to $16.1331. The low-float small-cap clinical stage gene therapy company saw its stock rally nearly 150 percent from Monday through Thursday. Formal news hasn't been announced this week that would support a triple-digit percentage rally (including more than 200 percent at one point on Thursday) but the quiet period following its initial public offering will expire on May 8. Celyad SA (NASDAQ: CYAD) shares gained 24.7 percent to $36.17. Celyad reported the publication of THINK study case report of CYAD-01 Induced Complete Remission in relapsed/refractory AML patient in haematologica. DMC Global Inc. (NASDAQ: BOOM) shares jumped 23.2 percent to $39.00 after the company reported upbeat Q1 results and issued upbeat Q2 guidance. eHealth, Inc. (NASDAQ: EHTH) gained 21.8 percent to $19.58 as the company posted upbeat Q1 results. Enova International, Inc. (NYSE: ENVA) climbed 20.4 percent to $27.20 following Q1 results. SVB Financial Group (NASDAQ: SIVB) shares jumped 18.2 percent to $304.135 following strong quarterly results. Knowles Corporation (NYSE: KN) gained 13.9 percent to $12.70 as the company reported Q1 results. Zymeworks Inc. (NYSE: ZYME) gained 13.8 percent to $17.36. Cocrystal Pharma, Inc. (NASDAQ: COCP) rose 11.8 percent to $2.336 after declining 25.09 percent on Thursday. ImmunoGen, Inc. (NASDAQ: IMGN) shares surged 11.7 percent to $11.75 after the company announced 'successful completion of interim analysis' for FORWARD I Phase 3 mirvetuximab soravtansine trial. Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) gained 9.5 percent to $12.70. Expedia Group, Inc. (NASDAQ: EXPE) shares rose 8.5 percent to $115.3801 after the company reported stronger-than-expected earnings for its first quarter on Thursday. Sprint Corporation (NYSE: S) shares rose 8.3 percent to $6.50. The stock moved higher after a Reuters report suggested ongoing merger talks with T-M

Hot Low Price Stocks To Invest In 2019: Natural Health Trends Corp.(NHTC)

Advisors' Opinion:
  • [By Max Byerly]

    Central Garden & Pet (NASDAQ: CENT) and Natural Health Trends (NASDAQ:NHTC) are both consumer discretionary companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers Natural Health Trends Corp (NASDAQ: NHTC) fell 7.8 percent to $19.80 in pre-market trading after rising 1.46 percent on Friday. Endocyte, Inc. (NASDAQ: ECYT) shares fell 6.6 percent to $11.41 in pre-market trading after climbing 4.18 percent on Friday. Quorum Health Corporation (NYSE: QHC) shares fell 6.2 percent to $5.15 in pre-market trading after tumbling 11.45 percent on Friday. Arcadia Biosciences, Inc. (NASDAQ: RKDA) fell 6.1 percent to $7.31 in pre-market trading after declining 3.35 percent on Friday. Boston Scientific Corporation (NYSE: BSX) fell 5.6 percent to $28.30 in pre-market trading. Evofem Biosciences, Inc. (NASDAQ: EVFM) fell 5.3 percent to $6.06 in pre-market trading after gaining 2.73 percent on Friday. Xerox Corporation (NYSE: XRX) shares fell 5.2 percent to $28.60 in pre-market trading. Xerox terminated its transaction agreement with Fujifilm and entered into a new agreement with Carl Icahn and Darwin Deason. JP Morgan downgraded Xerox from Overweight to Neutral. Cellcom Israel Ltd. (NYSE: CEL) fell 5.2 percent to $7.02 in pre-market trading. Cellcom is expected to release Q1 results on May 30, 2018. Perrigo Company plc (NYSE: PRGO) fell 4.5 percent to $74 in pre-market trading. Nabriva Therapeutics plc (NASDAQ: NBRV) shares fell 4 percent to $4.66 in pre-market trading
  • [By Shane Hupp]

    Natural Health Trends (NASDAQ:NHTC) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Friday.

Hot Low Price Stocks To Invest In 2019: Rockwell Collins, Inc.(COL)

Advisors' Opinion:
  • [By Logan Wallace]

    Raymond James & Associates raised its stake in Rockwell Collins, Inc. (NYSE:COL) by 1.0% in the second quarter, Holdings Channel reports. The fund owned 43,229 shares of the aerospace company’s stock after purchasing an additional 441 shares during the quarter. Raymond James & Associates’ holdings in Rockwell Collins were worth $5,822,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Mn Services Vermogensbeheer B.V. lifted its stake in Rockwell Collins, Inc. (NYSE:COL) by 1.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,616 shares of the aerospace company’s stock after purchasing an additional 400 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Rockwell Collins were worth $3,454,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

  • [By Lee Samaha]

    Meanwhile, UTAS reported yet another strong quarter of growth in commercial aftermarket, and with the forthcoming addition of Rockwell Collins (NYSE:COL), UTAS is well positioned to benefit from a buoyant commercial aerospace market.

  • [By Max Byerly]

    These are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

    Get Rockwell Collins alerts: Military Avionics Systems Market by leading Industry Players (Avidyne, GE Aviation, Honeywell, Rockwell Collins) and Growth Rate (2018-2025) (emailwire.com) Program aims to connect Maryland’s college students and international businesses (msn.com) Rockwell Collins (COL) Expected to Announce Earnings of $1.89 Per Share (americanbankingnews.com) KAI and Rockwell Collins team up for Korean Chinook upgrade (janes.com) German auto giant boosts bet on cutting-edge AR from Silicon Valley (finance.yahoo.com)

    Several research firms have commented on COL. Royal Bank of Canada reiterated a “hold” rating and issued a $143.00 price objective on shares of Rockwell Collins in a report on Friday, April 6th. Zacks Investment Research downgraded shares of Rockwell Collins from a “buy” rating to a “hold” rating in a research note on Thursday, February 22nd. Cowen restated a “hold” rating and issued a $135.00 price target on shares of Rockwell Collins in a research note on Friday, January 26th. Finally, Canaccord Genuity decreased their price target on shares of Rockwell Collins from $140.00 to $137.00 and set a “hold” rating on the stock in a research note on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $134.13.

Hot Low Price Stocks To Invest In 2019: PIMCO 25+ Year Zero Coupon US Trs ETF (ZROZ)

Advisors' Opinion:
  • [By ]

    My preferred fund here is Vanguard Extended Duration Treasury ETF (NYSE: EDV), which owns a basket of long-term, zero-coupon bonds. It's better-known, larger, and, most important, cheaper than its competitor PIMCO 25+ Year Zero Coupon U.S. Treasury Index Exchange-Traded Fund (NYSE: ZROZ). Both are poised to rally if deflation hits and the stock market falls. But EDV is cheaper, at only 0.07% expense ratio, compared with ZROZ's 0.15%, and so it's the one that makes the cut.

Hot Low Price Stocks To Invest In 2019: Innospec Inc.(IOSP)

Advisors' Opinion:
  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Innospec (IOSP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Motley Fool Transcribers]

    Innospec Inc  (NASDAQ:IOSP)Q4 2018 Earnings Conference CallFeb. 20, 2019, 9:00 a.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator

  • [By Logan Wallace]

    Press coverage about Innospec (NASDAQ:IOSP) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Innospec earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the specialty chemicals company an impact score of 46.0007935851604 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Tuesday, March 12, 2019

Best Financial Stocks To Own For 2019

tags:PPC,BAESY,ITG, An embattled Chinese financial giant that owns major assets in the United States including the Waldorf Astoria was just handed a $10 billion lifeline.

China's government said Wednesday that it would pump nearly 61 billion yuan ($9.7 billion) into Anbang. Beijing already seized control of Anbang in February and its former chairman is now on trial for fraud and embezzlement.

The Chinese insurance regulator said in a statement that the massive bailout was intended to shore up Anbang's business operations and protect its customers before the company seeks to raise new funds from private investors.

Anbang has drawn global attention in recent years for its aggressive pursuit of assets around the world under its former chairman, Wu Xiaohui, who built the firm up from a provincial car insurance business.

It's best known for its ambitious deal-making efforts overseas, including the $1.95 billion purchase of the Waldorf Astoria, a failed $14 billion bid for the Starwood hotel chain, and unsuccessful talks with the Kushner family business over a Manhattan office tower.

Best Financial Stocks To Own For 2019: Pilgrim's Pride Corporation(PPC)

Advisors' Opinion:
  • [By Ethan Ryder]

    President Energy (LON:PPC)‘s stock had its “corporate” rating reissued by FinnCap in a report released on Monday.

    Separately, Peel Hunt restated a “buy” rating and issued a GBX 10.50 ($0.14) target price on shares of President Energy in a report on Thursday, August 9th.

  • [By Max Byerly]

    BidaskClub upgraded shares of Pilgrim’s Pride (NASDAQ:PPC) from a strong sell rating to a sell rating in a report published on Tuesday.

    Several other equities research analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Pilgrim’s Pride from a hold rating to a buy rating and set a $27.00 target price for the company in a research report on Thursday, March 15th. BMO Capital Markets dropped their target price on shares of Pilgrim’s Pride to $31.00 and set a market perform rating for the company in a research report on Friday, February 16th. Morgan Stanley set a $25.00 target price on shares of Pilgrim’s Pride and gave the stock a hold rating in a research report on Tuesday, February 27th. Vertical Group raised shares of Pilgrim’s Pride from a hold rating to a buy rating in a research report on Wednesday, March 14th. Finally, Mizuho reissued a buy rating and issued a $28.00 target price on shares of Pilgrim’s Pride in a research report on Monday, April 23rd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $27.80.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Pilgrim’s Pride (PPC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Financial Stocks To Own For 2019: BAE Systems PLC (BAESY)

Advisors' Opinion:
  • [By Logan Wallace]

    BEACH ENERGY Lt/ADR (OTCMKTS:BCHEY) and BAE SYS PLC/S (OTCMKTS:BAESY) are both oils/energy companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

  • [By Lou Whiteman]

    The Marine Corps has selected BAE Systems (NASDAQOTH:BAESY) to manufacture its next-generation amphibious combat vehicle, dealing a major setback to the diversification plans of Science Applications International (NYSE:SAIC).

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on BAE SYS PLC/S (BAESY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Rich Smith]

    Britain's BAE Systems (NASDAQOTH:BAESF) (NASDAQOTH:BAESY) is a behemoth, doing more than $24 billion in annual business and valued in excess of $26 billion -- yet it's largely unknown to U.S. investors, a consequence of its stock being traded over the counter and not on major U.S. stock exchanges like the NYSE or Nasdaq. That could change, however, with BAE winning a big endorsement from investment megabank Morgan Stanley this morning.

  • [By Jason Hall, Rich Smith, and Travis Hoium]

    But that doesn't mean investors looking to add defense stocks to their portfolio should avoid the entire sector; there are opportunities to be had. These Motley Fool contributors have identified two companies with substantial military and commercial opportunities in AeroVironment, Inc. (NASDAQ:AVAV) and Boeing Co. (NYSE:BA), as well as undervalued British defense giant BAE Systems PLC (ADR) (NASDAQOTH:BAESY) as defense stocks worth watching closely this month. 

Best Financial Stocks To Own For 2019: Investment Technology Group, Inc.(ITG)

Advisors' Opinion:
  • [By Joseph Griffin]

    Investment Technology Group (NYSE:ITG) announced a quarterly dividend on Thursday, May 17th, RTT News reports. Investors of record on Wednesday, May 30th will be given a dividend of 0.07 per share by the financial services provider on Friday, June 15th. This represents a $0.28 dividend on an annualized basis and a yield of 1.23%.

  • [By Max Byerly]

    SEI Investments (NASDAQ: SEIC) and Investment Technology Group (NYSE:ITG) are both finance companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Monday, March 11, 2019

Durect Corp (DRRX) Files 10-K for the Fiscal Year Ended on December 31, 2018

Durect Corp (NASDAQ:DRRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Durect Corp is a biopharmaceutical company. It develops pharmaceutical products based on two categories which include new chemical entities and drug delivery programs. The lead candidate for the company is DUR-928. Durect Corp has a market cap of $111.820 million; its shares were traded at around $0.69 with and P/S ratio of 3.11.

For the last quarter Durect Corp reported a revenue of $8.04 million, compared with the revenue of $20.75 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $18.6 million, a decrease of 62.2% from the previous year. For the last five years Durect Corp had an average revenue growth rate of 10.3% a year.

The reported loss per diluted share was 16 cents for the year, compared with the loss per share of $0.19 in the previous year. The Durect Corp had an operating margin of -127.23%, compared with the operating margin of -4.55% a year before. The 10-year historical median operating margin of Durect Corp is -108.14%. The profitability rank of the company is 2 (out of 10).

At the end of the fiscal year, Durect Corp has the cash and cash equivalents of $31.6 million, compared with $29.4 million in the previous year. The long term debt was $20.5 million, compared with $12.6 million in the previous year. Durect Corp has a financial strength rank of 4 (out of 10).

At the current stock price of $0.69, Durect Corp is traded at 62.1% discount to its historical median P/S valuation band of $1.82. The P/S ratio of the stock is 3.11, while the historical median P/S ratio is 8.08. The stock lost 61.49% during the past 12 months.

For the complete 20-year historical financial data of DRRX, click here.

Sunday, March 10, 2019

Aviva PLC Sells 10,103 Shares of FleetCor Technologies, Inc. (FLT)

Aviva PLC reduced its stake in shares of FleetCor Technologies, Inc. (NYSE:FLT) by 23.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 32,849 shares of the business services provider’s stock after selling 10,103 shares during the period. Aviva PLC’s holdings in FleetCor Technologies were worth $6,101,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Capital Investment Advisory Services LLC bought a new position in shares of FleetCor Technologies in the fourth quarter valued at approximately $25,000. Lindbrook Capital LLC bought a new position in shares of FleetCor Technologies in the fourth quarter valued at approximately $28,000. AdvisorNet Financial Inc bought a new position in shares of FleetCor Technologies in the fourth quarter valued at approximately $53,000. Bremer Trust National Association bought a new position in shares of FleetCor Technologies in the fourth quarter valued at approximately $94,000. Finally, Advisors Asset Management Inc. bought a new position in shares of FleetCor Technologies in the third quarter valued at approximately $107,000. 67.39% of the stock is owned by hedge funds and other institutional investors.

Get FleetCor Technologies alerts:

FleetCor Technologies stock opened at $227.82 on Friday. FleetCor Technologies, Inc. has a 12 month low of $172.18 and a 12 month high of $234.98. The company has a current ratio of 0.86, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $27.99 billion, a P/E ratio of 22.94, a PEG ratio of 1.30 and a beta of 1.29.

FleetCor Technologies (NYSE:FLT) last posted its quarterly earnings data on Wednesday, February 6th. The business services provider reported $2.64 EPS for the quarter, missing the consensus estimate of $2.72 by ($0.08). FleetCor Technologies had a net margin of 33.35% and a return on equity of 25.73%. The firm had revenue of $643.40 million during the quarter, compared to analysts’ expectations of $620.45 million. During the same quarter in the previous year, the company posted $2.42 EPS. FleetCor Technologies’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, analysts predict that FleetCor Technologies, Inc. will post 11.01 earnings per share for the current year.

Several equities analysts have recently issued reports on FLT shares. BTIG Research started coverage on FleetCor Technologies in a report on Thursday, January 17th. They issued a “buy” rating and a $253.00 target price for the company. SunTrust Banks upped their target price on FleetCor Technologies from $240.00 to $260.00 and gave the company a “buy” rating in a report on Tuesday, February 19th. Deutsche Bank reduced their target price on FleetCor Technologies to $212.00 and set a “buy” rating for the company in a report on Tuesday, December 18th. Keefe, Bruyette & Woods reaffirmed a “buy” rating and issued a $214.00 target price on shares of FleetCor Technologies in a report on Monday, January 7th. Finally, ValuEngine raised FleetCor Technologies from a “hold” rating to a “buy” rating in a report on Friday, February 8th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $235.73.

COPYRIGHT VIOLATION NOTICE: “Aviva PLC Sells 10,103 Shares of FleetCor Technologies, Inc. (FLT)” was first posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/4209254/aviva-plc-sells-10103-shares-of-fleetcor-technologies-inc-flt.html.

FleetCor Technologies Profile

FleetCor Technologies, Inc provides commercial payment solutions in North America, Latin America, Europe, and Australasia. The company offers fuel payment solutions to businesses and government entities that operate vehicle fleets, as well as to oil and leasing companies, and fuel marketers. Its fuel payment products are in the form of plastic cards, electronic RFID tags, and paper vouchers to purchase fuel, oil, vehicle maintenance supplies and services, and building supplies.

See Also: Day Trading

Want to see what other hedge funds are holding FLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FleetCor Technologies, Inc. (NYSE:FLT).

Institutional Ownership by Quarter for FleetCor Technologies (NYSE:FLT)

Saturday, March 9, 2019

Top 5 High Tech Stocks To Buy Right Now

tags:China,CRHM,BAYZF,OI,TAIT,

Press coverage about Payment Data Systems (NASDAQ:PYDS) has been trending positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Payment Data Systems earned a news impact score of 0.32 on Accern’s scale. Accern also gave media coverage about the business services provider an impact score of 47.3249995564332 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

Top 5 High Tech Stocks To Buy Right Now: E-House(China)

Advisors' Opinion:
  • [By ]

    The world’s largest operating utility-scale solar projects are concentrated in China and India, according to IEEFA. Based on company and press reports, as well as its own estimates, those include:

    RankingProject NameSize MWCountryProponent 1Tengger Desert Solar Park1,547ChinaChina National Grid Zhongwei Power Supply Co2Kurnool Ultra Mega Solar Park1,000IndiaAndhra Pradesh Solar Power Corporation Pvt Ltd3Datong Solar Power Top Runner Base1,000ChinaMultiple4Yanchi Ningxia Solar Park1,000ChinaHuawei Technologies Co5Longyangxia Dam Solar Park850ChinaState Power Investment Corporation (China)6Adani Kamuthi Solar Plant648IndiaAdani Green7Solar Star579U.S.BHE Renewables8Topaz Solar Farm550U.S.First Solar9Desert Sunlight Solar Farm550U.S.NextEra Energy, GE Energy Financial & Sumitomo10Nova Olinda Solar Farm292BrazilEnel Green Power

    China added 53 gigawatts of the 98 gigawatts of new solar capacity built last year, a 31 percent increase from the total 2017, IEEFA said, citing Bloomberg New Energy Finance data. Meanwhile, the per unit cost of electricity over the life of a generating asset fell 15 percent year-on-year to $86 a megawatt hour.

Top 5 High Tech Stocks To Buy Right Now: CRH Medical Corporation(CRHM)

Advisors' Opinion:
  • [By Shane Hupp]

    Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp lessened its holdings in shares of CRH Medical Corp (NYSEAMERICAN:CRHM) by 36.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 867,243 shares of the company’s stock after selling 495,404 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp owned about 1.19% of CRH Medical worth $3,564,000 at the end of the most recent quarter.

Top 5 High Tech Stocks To Buy Right Now: Bayer Aktiengesellschaft (BAYZF)

Advisors' Opinion:
  • [By SEEKINGALPHA.COM]

    For the third quarter, the company reported cash and equivalents of $470.4 million, while net income came in at $50 million (includes a gain of $78.7 million from the Immunomedics' warrant). Without the one-time gain, its loss of $28.7 million would still be an improvement over net loss of $31.8 million for the same quarter last year. For the fourth quarter, the company is guiding for ADCETRIS sales in the range of $82 million to $84 million (total revenue of $128 million to $130 million). In addition to the growing opportunity for ADCETRIS (peak sales in excess of $1 billion) and the intriguing prospects of tucatinib, the company has a promising pipeline of ADC candidates and immuno-oncology assets. Partnered programs with the likes of AbbVie (NYSE:ABBV), Astellas (OTCPK:ALPMY), Genmab (OTCPK:GMXAY), Bayer (OTCPK:BAYZF), Genentech and many more also lend additional credibility to the story.

  • [By ]

    As of December 2017, Greenlight Re's major (10%+) long positions were General Motors (GM), Brighthouse Financial (BHF), gold (GLD), Bayer (OTCPK:BAYZF), and Mylan (MYL). It also holds a long position in Micron (MU), which was the best positive contributor to its portfolio in the first quarter of 2018. These long positions were balanced by shorts in Tesla (TSLA), Netflix (NFLX), and other "bubble basket" stocks. The portfolio is also short Assured Guaranty (AGO), a municipal bond insurer, a position which is hedged by a simultaneous long in Puerto Rican debt. Overall, the portfolio is 93% gross long and 65% gross short. Unlike most insurance portfolios, just 0.5% of investments are in debt instruments and, in fact, Greenlight Re's short portfolio was 11% allocated to sovereign debt.

Top 5 High Tech Stocks To Buy Right Now: Owens-Illinois Inc.(OI)

Advisors' Opinion:
  • [By Stephan Byrd]

    Riverhead Capital Management LLC grew its position in Owens-Illinois (NYSE:OI) by 376.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,233 shares of the industrial products company’s stock after buying an additional 81,550 shares during the quarter. Riverhead Capital Management LLC owned 0.06% of Owens-Illinois worth $2,236,000 at the end of the most recent quarter.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage gain ahead of the close was Owens-Illinois, Inc. (NYSE: OI) which traded up about 10% at $19.49. The stock's 52-week range is $16.22 to $25.90. Volume was nearly 3 million compared to the daily average volume of 1.3 million.

  • [By Todd Campbell, Rich Smith, and Neha Chamaria]

    There isn't much love for Owens Corning (NYSE:OI), Camping World Holdings (NYSE:CWH), and Oceaneering International (NYSE:OII) on Wall Street right now, but that could be about to change. Some of our top Motley Fool investors think the tough times that have soured the mood of institutional investors on these stocks could be ending and that could make these stocks bargains worth buying. 

Top 5 High Tech Stocks To Buy Right Now: Taitron Components Incorporated(TAIT)

Advisors' Opinion:
  • [By Max Byerly]

    Cool (NASDAQ:IFON) and Taitron Components (NASDAQ:TAIT) are both computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Friday, March 8, 2019

7 Dividend Stocks Already Rewarding Shareholders In 2019

When you write about investing as much as I do, sometimes it takes a little divine intervention to come up with ideas. Sometimes, I’ll borrow an idea from another writer. Recently, I saw an article about dividend stocks that have already increased their quarterly payment early in 2019.

If you can’t beat ‘em, join ‘em.

Eric Volkman, the author in question, recommended PepsiCo (NASDAQ:PEP), Walmart (NYSE:WMT) and TJX (NYSE:TJX). All Dividend Aristocrats, I like the latter two. Pepsi not so much.

However, I do appreciate the inspiration.

Now, on to the task at hand.

I’m looking for seven dividend stocks that I’d want to own that have announced a dividend increase in the first 64 days of the year. While they don’t have to be in the S&P 500, nor do they have to be a Dividend Aristocrat, they should have a market cap higher than $2 billion.

To help with diversification, I’ll try to get one stock for seven different sectors. I can’t guarantee that will be the case, but I’ll give it my best shot.

So, without further ado, here are my seven dividend stocks to own now.


Compare Brokers

EPR Properties (EPR)

On Jan. 16, 2019, EPR Properties (NYSE:EPR) announced a 4.2% increase in its monthly cash dividend. Payable as of Feb. 15, the monthly dividend is now 37.5 cents or $4.50 on an annual basis. It is the company’s ninth consecutive year increasing its dividend.

In February 2018, I recommended the REIT that specializes in experiential real estate, to own in good times and bad. At the time, it was yielding 7.7%. As of Mar. 5, 2019, it’s yielding 6.1%. That’s because it has appreciated significantly over the past year.

I’ve been a fan of EPR stock for a long time. I first recommended it in 2013 when it was trading in the $50s.

In 2019, EPR expects to generate adjusted funds from operation (FFO) of at least $5.30 a share. With all the interesting experiential real estate it owns or is developing, I continue to believe it’s a REIT to hold for the next 20 years.


Compare Brokers
Fastenal (FAST)

On Jan. 16, 2019, Fastenal (NASDAQ:FAST) announced a 3-cent increase in its quarterly dividend. Payable as of Feb. 27, the quarterly dividend is now 43 cents or $1.72 on an annual basis. As of Mar. 5, it yielded 2.8%.

The company first paid an annual dividend in 1991. It went to semi-annual dividends in 2003, and finally to quarterly dividends in 2011. It has also paid out special dividends in 2010 and 2012.

Fastenal is a wholesale distributor of industrial and construction supplies. Although I haven’t covered the company in recent years, its results from fiscal 2018 suggest it’s doing just fine.

In 2018, Fastenal grew revenues by 13% to $5 billion. On the bottom line, it increased earnings by 30% to $752 million. Both the company’s fastener and non-fastener products experienced healthy double-digit growth in 2018.

CEO Daniel Florness plans to double company sales to $10 billion. That ought to happen sometime in 2024. Perhaps earlier.


Compare Brokers
BlackRock (BLK)

On Jan. 16, 2019, BlackRock (NYSE:BLK) announced a 5% increase in its quarterly dividend to $3.30. Payable as of Mar. 21, the quarterly dividend works out to $13.20 on an annual basis. As of Mar. 5, it yielded 3.0%.

BlackRock CEO Larry Fink has become almost as famous for his annual letter to CEOs as he has for building the owner of iShares ETFs into a global asset management powerhouse. Fink’s 2019 letter was another classic.

Here’s the part that stands out for me:

“Companies must embrace a greater responsibility to help workers navigate retirement, lending their expertise and capacity for innovation to solve this immense global challenge. In doing so, companies will create not just a more stable and engaged workforce, but also a more economically secure population in the places where they operate,” Fink stated in BlackRock’s 2019 Letter to CEOs.

He’s not shy to say what’s on his mind. Some people don’t like it. I do. I believe it’s what sets BlackRock apart from other asset management and financial services firms.

Stand up for the little guy, and the little guy will give it his or her all for management. It’s a contract Fink believes should still exist within companies.

I couldn’t agree more.


Compare Brokers
Penske Automotive (PAG)

On Jan. 30, 2019, Penske Automotive Group (NYSE:PAG) announced a 1-cent increase in its quarterly dividend to 38 cents. Payable as of Mar. 1, the quarterly dividend works out to $1.52 on an annual basis. As of Mar. 5, it yielded 3.4%.

A penny increase in the quarterly dividend might not seem like a lot, but it adds up. That’s especially true when you’ve increased the dividend for 31 consecutive quarters. That’s not a typo.

There aren’t many companies that are that consistent about their dividend. Of course, would you expect any less from Roger Penske, the King of motor racing?

It hasn’t been smooth motoring for PAG stock over the past 26 months with negative total returns of 5.3% and 12.8% in 2017 and 2018, respectively; it’s nice to see Penske stock is up almost 9% year-to-date.

I recommended PAG stock last August as one of seven dividend growth stocks to buy. Although it has gone slightly backward since then, I see its juicy 3.4% dividend yield as an excellent check to earn while you wait for its stock to revert to the mean.


Compare Brokers
Brookfield Infrastructure Partners (BIP)

On Feb. 6, 2019, Brookfield Infrastructure Partners (NYSE:BIP) announced a 6.9% increase in its quarterly dividend to 50 cents. Payable as of Mar. 29, the quarterly dividend works out to $2.01 on an annual basis. As of Mar. 5, it yielded 5%.

Google the word “infrastructure,” and you get 718 million results.

Without infrastructure investments, economies wither and die. President Trump ran on an impressive platform in 2016 to grow the nation’s infrastructure, but very little has been done. That’s because America is broke and infrastructure is a costly adventure. It’s not for the faint of heart, hence the 5% dividend yield.

In fiscal 2018, BIP saw funds from operations (FFO) increase by 5% to $1.23 billion. Leading the charge was its energy business, which saw FFO increase by almost 29% in the past year. A significant part of the increase was the result of the company’s investment in a Canadian midstream business as well as a North American residential energy infrastructure company.

Like its affiliated former parent, Brookfield Asset Management (NYSE:BAM), BIP’s goal is to acquire assets at a reasonable price, get them operating both efficiently and profitably, and then sell those assets when prices are high. Then take the proceeds and do it again. Rince and repeat.


Compare Brokers
Church & Dwight (CHD)

On Feb. 5, 2019, Church & Dwight (NYSE:CHD) announced a 4.6% increase in its quarterly dividend to 22.75 cents. Payable as of Mar. 1, the quarterly dividend works out to 91 cents on an annual basis. As of Mar. 5, it yielded 1.4%.

What the maker of Arm & Hammer baking soda fails to provide in terms of dividend yield, it more than makes up for it with lots of capital appreciation.

Year-to-date, CHD stock is up 0.54%. Off to a slow start in 2019, Church & Dwight stock is in danger of a losing year, the first in more than a decade. Over the past ten years, CHD’s delivered an annualized total return of 19.6%, 250 basis points higher than the S&P 500.

That is why I believe Church & Dwight is the best consumer staples stock for investors to own for the long haul.


Compare Brokers
Best Buy (BBY)

On Feb. 27, 2019, Best Buy (NYSE:BBY) announced an 11% increase in its quarterly dividend to 50 cents. Payable as of April 10, the quarterly dividend works out to $2 on an annual basis. As of Mar. 5, it yielded 3%.

With the 11% increase, Best Buy has now increased its annual dividend payment for six consecutive years. It has also paid a dividend for 61 straight quarters.

Best Buy’s past issues including its ongoing fight with Amazon (NASDAQ:AMZN) appear to be very much in the rear window.

In 2018, Best Buy grew same-store sales by 4.8%, overall revenues increased 1.7% to $42.9 billion, and earnings-per-share on a non-GAAP basis increased by 20.4% to $5.32 a share. In 2019, it expects to generate at least $5.45 a share in earnings on $42.9 billion in revenue.

It might not be massive growth, but considering its shares were trading around $12 in 2012, it has come a long way. When I wrote about Best Buy in August 2013, it had online sales that accounted for 6.1% of its overall revenue. Today, it’s 21.9% or almost four times as much.

It’s one of the best comeback stories of the 21st century.

As of this writing, Will Ashworth did not hold a position in any of the aforementioned

Thursday, March 7, 2019

Addus HomeCare Corp (ADUS) Q4 2018 Earnings Conference Call Transcript

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Addus HomeCare Corp  (NASDAQ:ADUS)Q4 2018 Earnings Conference CallMarch 05, 2019, 9:00 a.m. ET

Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

Operator

Good day, ladies and gentlemen, and welcome to the Addus HomeCare Corporation Fourth Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this call is being recorded.

I would now like to introduce your host for today's conference, Dru Anderson. Ma'am, you may begin.

Dru Anderson -- Investor Relations, Corporate Communications, Inc.

Thank you, Heather. Good morning, and welcome to the Addus HomeCare Corporation fourth quarter 2018 earnings conference call. To the extent any non-GAAP financial measure is discussed in today's call, you will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP by going to the Company's website and reviewing yesterday's news release.

This conference call may also contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Addus' expected quarterly and annual financial performance for 2019 or beyond. For this purpose, any statements made during this call that are not statements of historical fact may be deemed to be forward-looking statements.

Without limiting the foregoing, discussions of forecast, estimates, targets, plans, beliefs, expectations, and the like are intended to identify forward-looking statements. You are hereby cautioned that these statements may be affected by important factors, among others, set forth in Addus' filings with the Securities and Exchange Commission and in its fourth quarter news release.

Consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

I would now like to turn the call over to the Company's President and Chief Executive Officer, Mr. Dirk Allison. Please go ahead, sir.

Dirk Allison -- President, Chief Executive Officer

Thank you, Dru. Good morning, everyone, and thank you for joining us for our fourth quarter conference call. With me today is Brian Poff, our Chief Financial Officer. I will begin with some general comments and then Brian, will discuss the fourth quarter results that we issued yesterday afternoon.

Following our comments, we would be happy to respond to any questions. As we announced yesterday, our solid operating performance continued in the fourth quarter of 2018. Revenue for the fourth quarter was $139.8 million compared to $112 million for the same period in 2017, an increase of 24.8%, driven by a combination of 2.4% organic growth and our acquisitions.

Adjusted earnings per diluted share for the fourth quarter of 2018 increased to $0.55 as compared to $0.45 for the same period in 2017, an increase of 22.2%. Our adjusted EBITDA for the fourth quarter of 2018 increased 17% to $12.3 million from $10.6 million and we had an adjusted EBITDA margin of 8.8% even with the continuing lack of a minimum wage price increase offset in Illinois.

As Brian will detail, our cash position continues to be strong, reflecting the efforts of our reimbursement team. Our fourth quarter same-store growth was below our ongoing target of 3% to 5%. This lower same-store growth was primarily the result of three items. First, the lack of an Illinois' minimum wage related rate increase, which we discussed last quarter; second, lower referrals in New Mexico due to the transition of MCOs who manage that state's Medicaid program; and three, lower referrals in Illinois, related to the ramp-up period for a major new coordinated care unit, which is an outsourced personal care referral company used by the state.

Importantly, we have seen referrals return to a more normal status in the first quarter of 2019, for both New Mexico and Illinois. We remain confident in our target same-store growth rate of 3% to 5% although we may be on the lower end of that range until we are able to obtain the Illinois minimum wage rate increase.

As we mentioned on our last call, the lack of an offset to the Chicago and South Cook minimum wage increase negatively affected our margins with fourth quarter margins impacted by approximately 70 basis points. Our team is diligently working with Illinois state leaders to pass a rate increase. At this time, there is a bill before the Illinois' legislature which would increase our reimbursement rate as we have requested. While we have no assurances that this bill will pass and become law, we continue to believe that state leadership understands the importance of passing this reimbursement increase to offset the mandated minimum wage increase the industry experienced July 1st of 2018.

Let me update you on our 2018 acquisitions. The transition of our Arcadia acquisition has gone well and is complete. Both teams worked hard during this period of time and we were able to complete this process on time and within budget as we had expected. We have closed the former headquarters of Arcadia and have moved all back-office functions to Addus' corporate and support center locations. Cost to effect this closing were booked in our fourth quarter as acquisition cost. We have realized full synergies as we head into our first quarter of 2019.

During the fourth quarter of 2018, we were also able to complete the transition of Ambercare, our Home Health and Hospice segment. While synergies were not as material as those for Arcadia, we were able to achieve our targets for transition during the quarter.

Severance and reorganization costs were recorded in our fourth quarter. During the fourth quarter, we also completed our conversion of all home health and hospice sites to Homecare Homebase, again on budget as we had planned. Our team is excited to be on this new platform, which should help our operational efficiencies in these two service lines.

Our Home Health segment represents $10.3 million in annualized revenues. There has been a lot of recent public discussion around PDGM and how to fix home health companies. Addus is certainly aligned with our other home health industry participants concerning this issue. However, I want you to understand that our exposure to PDGM is extremely small and based on our review we'll have no material effect on our financial results.

As we previously announced, Addus has signed a definitive agreement to acquire the assets of VIP Health Care Services, a New York City-based provider of personal care services. We are very excited that the team at VIP would be joining the Addus family. This acquisition is an important step to further our strategy of developing strong operations in the states where we operate.

Together with our South Shore operation on Long Island, we believe VIP will give us the coverage to offer full market services to our MCO partners in both Long Island and the Five Boroughs. Over the past few weeks, our team along with the VIP senior leadership had been involved with transition discussions, which we believe will help us as we complete this acquisition. We are awaiting state approval for the transaction and anticipate a close for this acquisition during the second quarter of 2019.

In addition to VIP, our development team continues to work with other potential acquisition targets. Currently, we are under a Letter of Intent with two potential acquisitions. One would strengthen the state in which we currently operate, while the other allows us to enter one of our targeted new states. Of course, there can be no assurance that we can complete either or both of these transaction or as to the timing of the transaction. We are excited about our ability to close additional acquisitions during 2019. Our pipeline remains strong, allowing us to focus on opportunities in the strategic markets that we have previously discussed.

On our last earnings call, I mentioned that CMS had announced that personal care services can be added by Medicare Advantage Plans to their care offerings beginning in 2019. While we feel that 2020 and '21 will be a timeframe when the majority of Medicare Advantage providers consider this service, we are now beginning our service to some of these providers.

We have contracts with two large Medicare Advantage Plans to provide personal care services to their members during 2019. Recently, we started to receive our first patients under these contracts. We are excited about working with these partners to gather the appropriate data, which will allow Addus to help Medicare Advantage providers as they continue to expand their offering around personal care. I believe that this is a positive step toward expanding the availability of our home care services under a value-based payment system and continues to indicate the increasing awareness by the federal government of the value of personal care services in improving the quality and lowering the cost of healthcare.

Before I turn this call over to Brian for a more detailed review of the fourth quarter performance, let me thank all the employees of Addus. We should all realize that our Company provides very important and much needed services to our patients at a low cost. Our services enable these patients to stay in their homes instead of progressing to much more expensive healthcare which occur in a less intimate setting. The good work that Addus does is only possible due to the commitment and hard work of each of our employees.

With that, let me turn the call over to Brian.

Brian Poff -- Executive Vice President, Chief Financial Officer

Thank you, Dirk, and good morning, everyone. Our financial results for the fourth quarter of 2018 demonstrated solid execution of our strategy as we continue to expand on the growing demand for home care services with an increasing level of profitable growth, both organically and from acquisitions.

We believe we are well positioned to continue this trajectory in 2019. We expect the impact of our growth from acquisitions to be strengthened by the anticipated completion of the VIP Health Care Services transaction in the second quarter of 2019. We also continue to evaluate and work toward other acquisition opportunities from an ongoing pipeline of potential transactions.

As Dirk mentioned, total net service revenues for the fourth quarter increased 24.8% to $139.8 million from $112 million for the fourth quarter of 2017.

Personal care revenues accounted for 93% of revenue for the fourth quarter and increased by 15.9% over last year. This growth reflected a 13.2% increase in billable hours per business day and just under 1% increase in revenue per billable hour. The remaining growth in revenue was attributable to our hospice and home health services with no contribution from these segments in the prior-year period. For 2018 these service lines added approximately $10 million in revenue for the fourth quarter and $25.7 million for the year after the acquisition of Ambercare in May.

Gross margin was 27.1% for the fourth quarter compared with 27.5% for the fourth quarter last year. However, with the adoption of ASU 2014-09, lowering our gross margin for the most recent quarter by 150 basis points, our comparable gross margin percentage to the prior year quarter was 28.6%. While we continue to be impacted by the Chicago minimum wage increase, we saw improved margins in our skill business during the quarter as we continue to focus on driving operational cost efficiencies.

G&A expense was 20.7% of revenue for the quarter compared with 17.6% for the fourth quarter last year. Approximately 90 basis points of the increase for the fourth quarter of 2018 was due to growth in M&A expenses, stock-based compensation, restructuring charges and severance and other costs compared to the fourth quarter of 2017.

An additional 40 basis points is related to the impact of the adoption of the accounting standards update. The remainder of the increase is primarily attributable to the G&A costs associated with our recent acquisitions.

The Company's adjusted EBITDA increased 17% to $12.3 million for the fourth quarter of 2018, compared to $10.6 million in the fourth quarter of 2017. Adjusted EBITDA margin was 8.8% compared with 9.4% for the fourth quarter of 2017. Adjusted net income per diluted share grew 22.2% to $0.55 for the fourth quarter from $0.45 for the fourth quarter of 2017.

The adjusted per share results for the fourth quarter of 2018 exclude the following; M&A transaction expenses of $0.11, restructuring charges of $0.02 and non-cash stock-based compensation of $0.07. As previously reported, our adjusted per share results for the fourth quarter of 2017 exclude writedown deferred tax asset of $0.12 related to the Tax Reform Act, gain on sale of joint venture divestiture of $0.01, M&A transaction expenses of $0.04, non-cash stock-based compensation of $0.04. Our tax rate for the fourth quarter of 2018 was 20.8%, fairly consistent with our expectations. For 2019, we continue to expect our tax rate to be in the low 20% range.

Our fourth quarter net cash from operations totaled $8.5 million. At December 31, 2018, we had $70.4 million in cash on hand and under our new credit facility announced last quarter, we continue to have capacity to support our acquisition strategy, with only $20 million in bank debt.

DSOs declined to 70 days at the end of the fourth quarter of 2018, compared with 71 days at the end of the third quarter. DSOs for the Illinois Department of Aging were 55 days at the end of the fourth quarter compared with 66 days at the end of the third quarter. This decline was partially offset by an increase in DSOs in our managed care business, primarily related to the client transitions in New York and New Mexico between MCOs. We expect our receivables in these markets to return to normal levels after the completion of the MCO transitions.

This concludes our prepared comments this morning, and thank you for being with us. I'll now ask the operator to please open the line for your questions.

Questions and Answers:

Operator

Thank you. (Operator Instructions) Your first question comes from Brian Tanquilut with Jefferies. Your line is open.

Brian Tanquilut -- Jefferies -- Analyst

Hey, good morning, guys. Congrats on a good 2018. So my first question for you guys. Dirk, as I think about labor, obviously, one of the -- key concerns or topics of discussion for investors, how are you thinking about labor pressures and how that affects you guys, whether it's translating from higher wage rates that you have to pay or whether it's Amazon or Chick-fil-A or whoever putting pressure on hiring. And then, if you don't mind just give me a profile on who the clinician is, and how that helps you differentiate from the other employers that I mentioned? Thank you.

Dirk Allison -- President, Chief Executive Officer

Thanks, Brian. Let me start with that, and see, if I can answer the question. We certainly, as all healthcare service providers have some level of a pressure due to the economy as it is today. Probably, our largest pressure has been the increase in minimum wage in some of our states, but at the same time, you know that we have a number of employees that are under union contracts in various states and so, once we negotiate a contract with those unions at whatever rate it is, at that point, everybody that comes to work for us there is, that rate is already established and we do not have to negotiate or pay higher rates to get those individuals. That's in the markets where the industry has been largely unionized about a state of the unions.

In addition to that, about 35% of our labor workforce are family members taking care of additional family members. So, it's really less a function of labor wage rates with them as opposed to our being able to actually hire them and get them trained and put them in the house to take care of their family. So once we get them on board, there's not a lot of shift between companies certainly not just because of -- there may be a small increase in hourly rate somewhere else, it's hard to transfer those patients.

So again, I think it's fair to say, we do face some pressure from the economy and competitors that you mentioned, but our union contracts as well as our makeup of our labor force with our family caregivers showed us to that to a degree.

Brian Tanquilut -- Jefferies -- Analyst

Okay. Dirk, just a follow-up to that. So in the states where you get increasing minimum wage, given the dynamics you just described with the unions. I mean, how does that normally translate? I know Illinois seems to be an issue right now, but it's temporary. But generally speaking, or in other states, what are you seeing in terms of the pricing movement between minimum wage changes and the rate of the states are reimbursing?

Dirk Allison -- President, Chief Executive Officer

Brian, generally, what you see, in most of the minimum wage increases are in states where the unions are fairly strong. That's not a totally exclusive, but it's the vast majority. And what we've seen there has -- we tend to see in those markets is first the unions negotiate with the state and get the minimum wage increased. And then as an after effect of that, then we start working with the unions to then go back to the states and try to get a bill passed that will cover the minimum wage increase that are coming out.

So in certain markets you may have stepped increases over a period of three to four years. Each year you have to negotiate with the state legislature to get those increases, very few states have put into effect a weight raise that's going to cover you or weight increase that's going to cover you for multiple years. They tend to do that on a year-by-year basis.

So it is -- we negotiate for the increase a little bit at generally after the minimum wage has already been passed into law, but I will tell you in the states where we're affected by minimum wage, the most, the union states, the union are partners with us, the union itself, they do partner with us working hand-in-hand with the leaders of the state to make sure that that price increase or that rate increase to us is given, because the alternative is, if a state fails to increase rates enough to offset these minimum wage increase then over a period of time companies are going to quit servicing that individual at home and that person is going to end up in a higher institutional life setting, a higher cost setting. So the state leadership understands that while it costs money, it's also, it's good for the population and overall good for the cost. So we've had good experience in the last three to four years of maintaining these increases to offset minimum wage with the exception as you know, there is a delay right now with Illinois, which is not unusual.

Brian Tanquilut -- Jefferies -- Analyst

Got it. Appreciate it. Last question from me, Dirk. You talked about Medicare Advantage briefly in your prepared remarks. So I figured your in the middle of other discussions with other payors right now on East Land (ph). If you don't mind just walking us through what those discussions they're like? What they're looking for? How they're thinking about structuring contracts? And how to pay you whether we're hearing pay-for-performance types of arrangement. If you don't mind, just give us some color on where you think that will go as we head into 2020? Thank you.

Dirk Allison -- President, Chief Executive Officer

Well, certainly, we believe Medicare Advantage is a nice potential upside for a Company like ourselves over the next three to five years. I think we've been very consistent in saying that. As far as negotiation, we have relationships with most of the large Medicare Advantage players, some of which offer other services like Medicaid, Managed Medicaid in various states, so while it may not be the same department or -- department of the company that we negotiate with, we do in a lot of cases already have inroads from a reputation standpoint. The negotiation with the Medicare Advantage obviously at this point in time is a little different than for Medicaid. In the Medicaid side, most MCOs are rate taker from the state, at least at first until the state eventually gives them ability to start tagging their network and maybe looking at how they reimburse the various participants or providers in that market.

Medicare Advantage is different, this is -- this is a benefit that the MA providers are offering to their membership. I believe long term, the Medicare Advantage providers are going to want us to go to more of a per member per month type reimbursement at risk-based approach. I think the problem we have now and they do is it's very early in the process. We've got to gather data to allow us to do that and we've got to decide and the Medicare Advantage providers have to decide what kind of services they're going to buy. Are they going to do a Medicaid type personal care service where as long as you can't do a couple of aspects of your activities of daily living, they're going to give you coverage for multiple months or is it going to be more of an acute offering it first, so that it's much more limited in scope as to what their offering as far as personal care. So I'm not trying to evade the subject on the negotiation, it's just different with every Medicare Advantage company based on what they're looking to offer to their members.

And I think over a period of time, the real upside for a company like Addus has when the Medicare Advantage shift from thinking that personal care is a benefit to sell the plan to their members and start thinking in terms of personal care is a way to reduce the medical loss ratio that they experience for their members. So we're hoping to see that occur over the next couple of years.

Brian Tanquilut -- Jefferies -- Analyst

All right. Thanks, Dirk.

Operator

Thank you. Your next question comes from Frank Morgan with RBC Capital Markets. Your line is open.

Frank Morgan -- RBC Capital Markets -- Analyst

Good morning. Appreciate some of that initial color about that acquisition backlog. But just curious if you could give us a little more color on the actual service lines that you're seeing most of the likely activity, and are you seeing any new entrants in terms of competition for deals and any changes in valuations and given this MA opportunity?

Dirk Allison -- President, Chief Executive Officer

Yeah, Frank, the two deals that we mentioned under Letter of Intent are majority personal care services. They may have a slight segment -- small segment of the other two offerings that we have, but by and large their personal care services, an important markets for us. The rates that we're having to pay have not changed, very steady at that 6 times little, maybe 6 times to 7 times EBITDA, and so we're very -- that's been very consistent for us as related to the majority of the personal care services.

As far as competition, honestly at this point in time, especially related around the personal care acquisitions, we've not seen an increase and competition has been very steady. Now, that's different if we were out looking at just a hospice acquisition as you know that that market has been pretty hot and very frothy as far as the rate you have to pay to get those companies.

And there's been a lot of PE firms out there looking for those. So if we were in a hospice, I would have a different answer. But because these are -- vastly the majority of it is personal care, it's not that competitive.

Frank Morgan -- RBC Capital Markets -- Analyst

Got you. And with your -- you called out, I think, $50 million of revenue with this pending VIP deal. When we get to the end of the year, what do you think would be a good year for acquisitions, I mean, what kind of number would it take to say in terms of just acquired revenue or transact whatever basis you want to look at it really under a sort of a best case scenario. What kind of growth do you think you might be able to log?

Dirk Allison -- President, Chief Executive Officer

Well, understanding I'm not giving you guidance by saying this. But just trying to answer your question is, honestly as I can, I think it would probably change depending on who is giving you the answer. I would tell you -- I personally would like to see us bring in at least $100 million of revenue during 2019. I think if you were talking to our conservative CFO, he would tell you more like $75 million or so, so we'll go with the $100 million. How about that?

Frank Morgan -- RBC Capital Markets -- Analyst

Yeah. I like that, nice round number. Just one -- last one and I'll get back in the queue. On the Homecare Homebased conversion, any -- I know this is a small part of your business right now, but any disruption in a sense have you notice as a result of that, and I'll hop off. Thanks.

Dirk Allison -- President, Chief Executive Officer

Well, I think, anytime. We went through two things related to Ambercare's hospice services and home healthcare services too. The team by the way did a great job during this transition of really hang in there working hard, but I think we faced two factors that probably did reduce our ADC in the hospice side a bit, a small bit. And that was, one, the Homecare Homebased conversion, you never go through something that major material without a little bit of slowdown, just due to the fact that the people that operate the company every day are really tied up in getting that conversion.

And the second thing for us was, we had a plan when we acquired Ambercare, that we were going to look at the sales force, the sales team, and that we were going to make changes to get into a place we wanted to be. And so during the third and fourth quarter of this year we had a lot of changes in our hospice sales force that have now in the first quarter really started to pay benefits. So I would say, Homecare Homebased was a slight disruption, but other things also added to that.

Operator

Thank you. Your next question comes from Matthew Gilmore with Robert Baird. Your line is open.

Matthew Gillmor -- Robert W. Baird -- Analyst

Hi. Thanks for the question. Maybe asking about the organic growth trend, I wanted to follow up on -- some of the temporary items that you mentioned that impacted referrals in New Mexico and Illinois. I think I understand the dynamics in New Mexico with the new MCOs, but could you provide a little bit more details on the issue with Illinois? I think you mentioned a change in vendor for coordinated care units. So just sort of wondering what that is?

And then if you could also sort of size the impact from some of these temporary items, it sounded like you maybe be closer to 3% without those items. But I just wanted to confirm if that was correct.

Dirk Allison -- President, Chief Executive Officer

Yes. We think we would been above 3% had these items not occurred. Let me explain to you the CCUs in Illinois. The way Illinois operates is that they outsource their referral system for personal care to companies that are called coordinated care units. These companies actually go out and do assessments of potential patients looking at their -- what activities of daily living, they are deficient and cannot do for themselves. And then based on what they find, they develop a plan of care and then they'll contact the company like Addus and they will give us that plan of care and we'll pick up the patient.

What happened during the fourth quarter, one of our large CCUs sold and was acquired by an out of state company, and it took a period of time for that new company to ramp up and get back to where they were handling as many referrals as we have seen the company handled prior to the sale, that now has occurred. In the first quarter we don't have a lot of experience really, well I guess, we're halfway through the quarter, so we have seen an increase in our referrals, both in New Mexico and Illinois back toward more normal levels. So we're comfortable that our -- 3% to 5% is still a good number. We believe on an annual basis that won't be a problem.

The first half of the year, honestly could be toward the lower part of that, just because as we mentioned, a large part of our business is in Illinois and any rate increase that we're working on the potential effective the date we've been talking to the state about is July 1. So we will go through the first two quarters without that increase.

Matthew Gillmor -- Robert W. Baird -- Analyst

Got it. Thanks. And then, as a follow-up to the acquisition pipeline discussion you had with Frank. I guess, I just wanted to confirm that these two discussions you're having these two LOIs that those are -- I guess, relatively advanced and I guess the reason I ask is -- I assume you're under LOI pretty frequently and maybe you can correct me if I'm wrong. And then, would you characterize those deals as being sort of on the larger side of what you've done the last couple of years or on the smaller side, just to sort of size them up.

Dirk Allison -- President, Chief Executive Officer

We don't always have signed a lot of Letter of Intent. We try to do enough work beforehand. That's not to say we don't sign Letter of Intent, and we don't close the deal, that does happen, I want to be very clear with that. But in these two instances while we can't guarantee we will get to close, we are fairly long, fairly far long on our process of working through the final stages of due diligence and trying to get to that final definitive document. As far as the size -- when you look at -- size going all the way back to options, in 2017, we've acquired things from about $18 million to $20 million of revenue upwards of $50 million of revenue. We've acquired some even smaller $5 plus million. I would say these are in that mid type range, not the biggest we've done, but certainly not the smallest either.

Matthew Gillmor -- Robert W. Baird -- Analyst

Got it. And then, last question, you talked about the -- so the Medicare Advantage contracts that you are live with in 2019. I guess, I just wanted to confirm that those are in states where you already provide services. And then as you're talking with Medicare Advantage plans, is that a state by state discussion or are they looking for more national type partners.

Dirk Allison -- President, Chief Executive Officer

Well, they are in states in which we operate, but you realize we operate in 24 states and we have probably 8 to 10 states that are -- we're fairly large and cover majority of the state, especially as we continue to increase that with these acquisitions. So it's nice for us. Our team has done a great job of going in and working with the Medicare Advantage providers specifically around maybe a particular state that they're big in and we're big in. But we're also always looking for opportunities to add our services elsewhere where we may be able to partner with them. That's a strong word, because it's not an official partnership. But certainly it's a relationship where if we can continue to grow in markets where they have a large population of Medicare Advantage, we would believe we would get our fair share of those patients going forward.

Matthew Gillmor -- Robert W. Baird -- Analyst

Got it. Thank you.

Operator

Thank you. (Operator Instructions) Your next question comes from Dana Hambly with Stephens. Your line is open.

Dana Hambly -- Stephens -- Analyst

Hey, thanks for taking the questions. Dirk, just to clarify the two Medicare Advantage contracts you just started, are those multistate or are those limited to single state right now?

Dirk Allison -- President, Chief Executive Officer

Those are multistate.

Dana Hambly -- Stephens -- Analyst

Those are multi. Okay. And just as far as the process, is it similar with the Medicare Advantage to what you're doing with Medicaid right now insomuch as you're approved for X number of billable hours and then it's your job to go deliver that or is it different with with MA?

Dirk Allison -- President, Chief Executive Officer

Today, it's that way. I do want to say, Dana, I think long term, a real opportunity for a company like ours with our size is if we can ever gather the data and go to more of a per member per month service pricing model, I think that will help us not only have the opportunities for possibly increased margins a bit, but also be an offering that I think more Medicare Advantage providers would like to see in the future.

Dana Hambly -- Stephens -- Analyst

Okay. And is the current structure kind of similar to what you're seeing in maybe some of your larger Medicaid states right now with regarding the number of billable hours?

Dirk Allison -- President, Chief Executive Officer

Well, I don't think the Medicare Advantage you can -- itself, you can model after our Medicaid business. In our Medicaid business we stay for about 26 months with patient and we provide right at 60 hours of average care per month.

Dana Hambly -- Stephens -- Analyst

Okay.

Dirk Allison -- President, Chief Executive Officer

You're going to see a much shorter duration of care, maybe 30 days, and you're going to see potentially less hours. So from a revenue standpoint today, again, realized most the Medicare Advantage providers today are looking at this as a benefit to sell the plan. I don't think they really yet said, by offering more services in this particular area, we can reduce our overall medical loss ratio through less emergency room visits, maybe less hospital days. I think that will come, and as that comes you may see the way with the service levels between Medicaid and Medicare get more similar. But today, they are truly a different service level.

Dana Hambly -- Stephens -- Analyst

Okay. All right, that's helpful. Is there any concern on the switch to the new CCU in Illinois to this out of state entity that their criteria will change on billable hours?

Dirk Allison -- President, Chief Executive Officer

No, we're not concerned at all. We know them very well. We've worked with them. I just think it was a matter of any time takeover company and change management, and you got to bring your systems and it takes you a bit to get up and going. And I think they've actually done a good job doing that. It just took them a little bit of time during the fourth quarter.

Dana Hambly -- Stephens -- Analyst

Okay. And then lastly, the New York narrow networks. I believe they narrowed last year as I recall, I think that's supposed to narrow again this year. Just correct me, if I'm wrong there, but also could you just -- what's the general criteria for remaining within one of these narrow networks. And have you seen any other states thinking about this?

Dirk Allison -- President, Chief Executive Officer

Well, I think the criterion again, I think each MCO can make their own decisions. I think it would have to do with the coverage, what kind of coverage can you give them, if they're limit to it certain number of providers, they want providers that can cover their entire membership population. So a company like Addus that has, let's take Long Island as an example, we probably can service more locations on Long Island than any of our competitors, which gives us a real advantage when the MCOs are looking to reduce the network. Now if we weren't providing the proper service levels, if we had issues with our patients complaining to the MCOs about us not showing up, us not doing the right service level, us not following the plan of care, then I don't care how much geographic coverage you provide, I think you would be in trouble. So you start with providing the proper and appropriate service and then hopefully, our size and geographic coverage allows us to stay in these networks.

As far as other states that we operate in, I -- we are not aware today of any states that are looking to, at this point in time, limit the size of their provider network, again realize and I think you do Dana, that is an advantage to a company like ours that has the coverage size and hopefully, the expertise in the service area. So we would see, in other states what we are seeing in Long Island today, and that is really nice growth. And a lot of that growth coming with caregivers, that is very important as we have this -- the difficulty of finding caregivers today.

Dana Hambly -- Stephens -- Analyst

All right. Thanks, guys.

Operator

Thank you. And I'm showing no further questions at this time. I'd like to turn the call back over to Mr. Dirk Allison, President and Chief Executive Officer for closing remarks.

Dirk Allison -- President, Chief Executive Officer

Thank you, operator. I want to thank everyone today for their interest in Addus and for participating on our earnings call. We hope you have a great week. Thank you.

Operator

Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you all may disconnect. Everyone have a wonderful day.

Duration: 39 minutes

Call participants:

Dru Anderson -- Investor Relations, Corporate Communications, Inc.

Dirk Allison -- President, Chief Executive Officer

Brian Poff -- Executive Vice President, Chief Financial Officer

Brian Tanquilut -- Jefferies -- Analyst

Frank Morgan -- RBC Capital Markets -- Analyst

Matthew Gillmor -- Robert W. Baird -- Analyst

Dana Hambly -- Stephens -- Analyst

More ADUS analysis

Transcript powered by AlphaStreet

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.